Myriad Genetics has patented a method for predicting breast cancer prognosis by analyzing RNA expression levels of specific genes in tumor samples. The method helps determine if patients with certain tumor types will benefit from cytotoxic chemotherapy, guiding personalized treatment decisions. GlobalData’s report on Myriad Genetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Myriad Genetics, Personalized medicine biomarkers was a key innovation area identified from patents. Myriad Genetics's grant share as of February 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Prognosis of breast cancer treatment based on gene expression
The granted patent (Publication Number: US11913078B2) outlines a method for treating patients with estrogen receptor positive and HER2 negative breast tumors. The method involves determining the patient's suitability for cytotoxic chemotherapy by analyzing RNA expression levels of specific marker genes, including AURKA and a selection from a list of genes. Based on the test combined score derived from this analysis, patients are either administered cytotoxic chemotherapy or non-cytotoxic therapy. The patent also covers methods for classifying tumors based on responsiveness to cytotoxic chemotherapy, involving RNA extraction, gene amplification, and analysis to determine the tumor's suitability for specific treatments, including endocrine therapy like tamoxifen or aromatase inhibitors.
Furthermore, the patent details a method for analyzing tumor samples from patients with estrogen receptor positive and HER2 negative breast tumors. This involves extracting RNA, amplifying a set of marker genes, determining RNA expression levels, and combining these levels to assess responsiveness to cytotoxic chemotherapy. The test combined score obtained from this analysis helps classify tumors as either responsive or non-responsive to cytotoxic therapy based on a reference combined score. The patent emphasizes the importance of personalized treatment approaches based on genetic markers, allowing for tailored cytotoxic or non-cytotoxic therapies depending on the individual patient's profile and tumor characteristics.
To know more about GlobalData’s detailed insights on Myriad Genetics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
